Drug major Dr Reddy's Laboratories Ltd on Friday reported a 7 per cent year-on-year (YoY) rise in net profit at Rs 1,347 crore for the September quarter, compared with Rs 1,255 crore in the same period last year.

Revenue from operations grew 10 per cent YoY to Rs 8,828 crore, up from Rs 8,038 crore in the corresponding quarter of the previous fiscal. Advertisement

"Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRT) portfolio, which helped offset the decline in US Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and pursuing business development initiatives," said GV Prasad, Co-Chairman and MD of Dr Reddy's.

Separately, the company announc

See Full Page